RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
发明人:
BAE, Yong-Soo,배용수,JEONG, Yideul,정이들,KANG, Myeongho,강명호,BYEON, Se Eun,변세은
申请号：
KRKR2016/012289
公开号：
WO2017/074118A1
申请日:
2016.10.28
申请国别(地区):
WO
年份:
2017
代理人:
摘要：
The present invention relates to a pharmaceutical composition containing dendritic cells expressing Foxp3 for regulating immunity. The present invention has confirmed the efficacy, in a state of immune imbalance, of using Foxp3+ dendritic cells (fxDC) present only in the blood to inhibit proliferation of T cells and restore and maintain immunological homeostasis by activating CD8+ regulatory T cells (CD8+ Tregs), and as such, the present invention is anticipated to allow, with respect to preventing and treating immune disorders, a targeted treatment by employing a more fundamental approach.La présente invention concerne une composition pharmaceutique contenant des cellules dendritiques exprimant Foxp3 pour réguler limmunité. La présente invention a permis de confirmer lefficacité, dans un état de déséquilibre immunitaire, de lutilisation de cellules dendritiques Foxp3+ présentes uniquement dans le sang afin dinhiber la prolifération de lymphocytes T, et de restaurer et maintenir lhoméostasie immunologique par lactivation de lymphocytes T régulateurs des CD8+ (Tregs CD8+), et, en tant que telle, la présente invention est susceptible de permettre un traitement ciblé, quant à la prévention et au traitement de troubles immunitaires, au moyen dune approche plus fondamentale.본 발명은 Foxp3를 발현하는 수지상 세포를 포함하는 면역 조절용 약학적 조성물에 관한 것이다. 본 발명은 혈액에서만 존재하는 Foxp3+ 수지상 세포(fxDC)를 이용하여, 면역 불균형 상태에서, CD8+ 조절 T 세포 (CD8+ Treg) 의 활성화를 통한 T 세포 증식 억제효과 및 면역 항상성 회복 및 유지 효과를 확인하였는바, 면역 질환의 예방 또는 치료에 있어서, 보다 근본적으로 접근하여 타겟치료를 할 수 있을 것으로 기대된다.
